Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03896620 · ClinicalTrials.gov registry record

Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma

A clinical trial of Sarcoma, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT03896620 is a study of Sarcoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 50 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03896620, a study of Sarcoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this procedure poses physical risks to the patient. A tissue biopsy also needs to be recollected at various time points in order to assess if the patient is responding to treatment. In this project, the investigator would like to collect blood samples in addition to the sample of the tumor that will be collected before treatment is started. The investigator would like to analyze both blood and tumor, in hopes of identifying new biomarkers of sarcoma that can help the study doctors better diagnose sarcoma for patients in the future without needing to collect a piece of their tumor. A biomarker is something found in the blood, other body fluids, or tissues that can be used to measure the progress of disease, how a treatment is working, or its likelihood of being successful. In this project, the investigator would like to compare ctDNA from blood to the DNA in the tumor. ctDNA, or circulating tumor DNA, is DNA originating from the tumor that is present in the blood. It can be assessed by taking an additional sample of blood when it will be collected for normal laboratory tests. These biomarkers may also help the study doctors detect how a patient is responding to their treatment or help predict their response to future treatment.

Conditions Studied

Sarcoma

Interventions

  • DRUG Chemotherapy
  • DEVICE Preoperative RT
  • DEVICE Postoperative RT
  • OTHER Surgery

Study Locations (1)

Wisconsin

  • Froedtert Hospital & the Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-06-18
Est. Completion 2026-06-01

Sponsor

Medical College of Wisconsin

447 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03896620

The ClinicalTrials.gov registry entry for NCT03896620 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.

NCT03896620 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03896620 about?

NCT03896620 is a clinical study titled "Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma". A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment. However, tissue biopsy collection can be challenging (depending on the location of the tumor), and this proc...

What is the current status of trial NCT03896620?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2019-06-18. Estimated completion is 2026-06-01.

What conditions does trial NCT03896620 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT03896620?

The interventions under investigation include: Chemotherapy (DRUG), Preoperative RT (DEVICE), Postoperative RT (DEVICE), Surgery (OTHER).

Who is sponsoring clinical trial NCT03896620?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03896620 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Wisconsin

All trials with a study site in Wisconsin

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.